NCT Number: NCT00002106
A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3
To evaluate the effect of ranitidine on immunologic indicators in asymptomatic HIV-1 infected patients with CD4 counts of 400-700 cells/mm3.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Pacific Oaks Med Group, Sherman Oaks, California, United States
About this study
Patients are randomized to receive either ranitidine or matching placebo bid for 16 weeks, with follow-up every 4 weeks through week 20.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients must have:
- Asymptomatic HIV-1 infection.
- CD4 count of 400-700 cells/mm3.
Exclusion criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Significant illness.
- Acute illness at randomization.
- Hemodialysis.
Prior Medication:
Excluded:
- Antiretroviral use within 60 days prior to study entry.
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Glaxo Wellcome
Industry
Registry information
Important dates
- First posted
- Aug 31, 2001
- Registry last updated
- Jun 24, 2005
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Improving the Reach & Effectiveness of Smoking Cessation Services Targeted to Veterans Living With HIV
NCT04505371
Behavior, Blood-Borne Infections
Seattle, Washington, United States
View Trial DetailsSpotting Syphilis: A Dual Point-of-Care Syphilis Screening Initiative in a Low-Resource Healthcare Setting
NCT07498153
Bacterial Infections, Bacterial Infections and Mycoses
Houston, Texas, United States
View Trial DetailsA Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection
NCT05328765
Anal Squamous Cell Carcinoma, Anus Diseases
Buenos Aires, Argentina
View Trial DetailsTransmasculine One-on-One and Group Empowerment for Targeted HIV Reduction
NCT06182280
Adherence, Medication, Behavior
Boston, Massachusetts, United States
View Trial Details